TABLE 6. Studies of MAOIs in major
depression patients resistant to TCAs
Ref. |
Sample |
Medication and designa |
Medication resistant toa |
Results |
Himmelhoch
et al. (44) |
21 depressed patients (13 BP, 11UP) |
Tranycypromine (30 mg) added to lithium; open trial; ? duration |
Recent
(11) or past (8) trials TCA |
16 of 21 (76%) responders |
Price et al. (82) |
12 depressed inpatients (6 psychotic UP, 2 BP) |
Tranycypromine (30-60 mg) added to Li; open crossover with blinded rater; 4 or more weeks |
Lithium added to desipramine or adinazolam or bupropion |
8 of 12 (67%) responders |
Georgotas et al. (36) |
20 depressed, UP patients |
Phenelzine (15-75 mg); open crossover, 2-7 weeks |
Imipramine 150-300 mg or equivalent for 1-8 months |
11 of 20 (55%) responders |
Nolen et al. (69) |
26 depressed, UP patients |
Tranycypromine (82 mg) or L-5HTP; open randomized crossover, 4weeks |
Imipramine > 150 mg or equivalent followed by trials oxaprotiline, fluvoxamine, and sleep deprivation |
TRP: 7 of 14 (50%) responders (L-5HTP; 0 of 12 responders) TRP > L-5HTP |
Nolen et al. (67) |
13 depressed, UP patients |
Tranycypromine (71 mg) or nomifensine; double blind randomized crossover, 4 weeks |
Imipramine > 150 mg followed by trials of oxaprotiline, fluvoxamine, and sleep deprivation |
TRP; 4/8 (50%) responders nomifensine: 0/5 responders TRP > NOM |
Nolen et al. (70) |
39 major depression inpatients (31 UP, 8 BP) |
Brofaramine (218 mg; n = 22), tranylcypromine (85 mg; n = 17) |
Prospective trial of nortriptyline or maprotiline |
TRP 10/17 (59%) BRO: 13/22 (59%) BRO better tolerated than TRP. |
Ryan et al. (88 ) |
23 major depression adolescent outpatients, ages 11-18 |
Phenelzine (n = 1 alone; + TCA, n = 7) tranylcypromine (n = 3) alone; + TCA, n = 12); open trial; ? duration |
Adequate doses of TCAs for {ewc MVIMG,
MVIMAGE,!greateq.bmp} 6 weeks |
12 of 23 (56%) responders |
McGrath et al (58) |
46 depressed outpatients, UP (atypical) depression |
Phenelzine (60-90 mg); double blind randomized crossover, 6 weeks |
Imipramine (200-300 mg) for 6 weeks |
31 of 46 (67%) responders PHZ > IMI |
Thase et al. (107) |
42 patients outpatients, UP (atypical) depression |
Phenelzine (n = 4; 60 mg) or tranylcypromine (38.5 mg); open crossover, 6 weeks |
Imipramine (257 mg) and interpersonal psychotherapy |
17 of 26 (65%) responders |
Thase et al. (108) |
12 patients with anergic BP depression |
Tranylcypromine (30-60 mg), double blind, randomized
crossover, 6 weeks |
Imipramine (242 mg/ day) |
9 of 12 (75%) responders TRP > IMI |
Adapted
from Devlin and Walsh (24).
aDosage refers to mean prescribed dosage, where provided, or to dosage
range.
published 2000